This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Why Encompass Health (EHC) is Down 2.4% Since Q1 Earnings Beat
by Zacks Equity Research
Encompass Health Corporation (EHC) looks to unveil eight additional de novo locations this year and increase its bed count.
Vermilion Energy (VET) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.
Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why
by Zacks Equity Research
Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.
Ring Energy (REI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
A favorable commodity pricing scenario is likely to have aided Ring Energy's (REI) earnings in Q1.
Should You Buy Ascendis Pharma (ASND) Ahead of Earnings?
by Aditi Saraogi
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.